BiotechTube

SHR7280 Tablet + SHR7280 Placebo Tablet

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Endometriosis

Conditions

Endometriosis, Uterine Fibroids, Assisted Reproduction

Trial Timeline

May 19, 2025 → Jul 5, 2025

NCT ID
NCT06969664

About SHR7280 Tablet + SHR7280 Placebo Tablet

SHR7280 Tablet + SHR7280 Placebo Tablet is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Endometriosis. The current trial status is completed. This product is registered under clinical trial identifier NCT06969664. Target conditions include Endometriosis, Uterine Fibroids, Assisted Reproduction.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06969664Phase 1Completed

Competing Products

20 competing products in Endometriosis

See all competitors
ProductCompanyStageHype Score
ASP1707 + Placebo + Leuprorelin acetateAstellas PharmaPhase 2
52
40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateSumitomo PharmaPhase 3
77
SHR7280 TabletsJiangsu Hengrui MedicinePhase 1
33
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
33
SHR7280 + Placebo oral tabletJiangsu Hengrui MedicinePhase 1/2
41
Placebo + ElagolixAbbViePhase 2
52
Elagolix + Placebo + Combined Oral ContraceptiveAbbViePhase 3
77
Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETAAbbViePhase 3
77
ElagolixAbbViePhase 3
77
elagolix + estradiol/norethindrone acetate (E2/NETA)AbbViePhase 3
77
Elagolix + placeboAbbViePhase 2
52
ElagolixAbbViePhase 3
77
Elagolix + Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) + Placebo to Elagolix + Placebo to DMPA-SCAbbViePhase 2
52
elagolixAbbViePhase 3
77
ElagolixAbbViePhase 3
77
Leuprorelin Acetate Depot + Elagolix + Placebo to Elagolix + Placebo to Leuprorelin AcetateAbbViePhase 2
52
Gefapixant + Placebo + NaproxenMerckPhase 2
52
BGS649 + PlaceboNovartisPhase 2
52
Active treatment with a high dose of BGS649 + Active treatment with a low dose of BGS649 + Placebo treatment to blind studyNovartisPhase 2
52
LetrozoleNovartisPhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85